|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,903.35 INR | +0.14% |
|
+2.89% | +27.63% |
| 07-09 | India's Dr Reddy's says semaglutide shipping disruption to last until at least late October | RE |
| 07-09 | India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice | RE |
| Market Cap | 1,660B 17.4B 15.22B 14.04B 12.97B 24.6B 25.02B 168B 65.87B 818B 65.33B 63.91B 2,810B | P/E 2027 * |
70.9x | P/E 2028 * | 52.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1,774B 18.6B 16.27B 15.01B 13.86B 26.3B 26.74B 179B 70.41B 874B 69.84B 68.32B 3,004B | EV / Sales 2027 * |
9.31x | EV / Sales 2028 * | 8.14x |
| Free-Float |
28.81% | Yield 2027 * |
0.62% | Yield 2028 * | 0.7% |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | +0.14% | ||
| 1 week | +2.89% | ||
| Current month | +6.07% | ||
| 1 month | +9.86% | ||
| 3 months | +17.95% | ||
| 6 months | +23.73% | ||
| Current year | +27.63% |
| 1 week | 4,747.2 |  | 4,948.95 |
| 1 month | 4,375.95 | | 4,948.95 |
| Current year | 3,724.1 | | 4,948.95 |
| 1 year | 3,314.2 | | 4,948.95 |
| 3 years | 1,771.35 | | 4,948.95 |
| 5 years | 1,242.5 | | 4,948.95 |
| 10 years | 571.75 | | 4,948.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 2025-07-31 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 2018-08-31 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 2026-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 2014-07-29 | |
| Director/Board Member | 46 | 2018-02-07 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 2019-03-06 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24-11-28 | Buy | Chief Operating Officer | 930,144 | 0.2748% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.14% | +2.89% | +46.85% | +156.30% | 17.4B | |
| -2.33% | -2.09% | +50.33% | +162.29% | 1,060B | |
| -0.82% | -2.30% | +62.97% | +61.11% | 619B | |
| -0.73% | -4.98% | +27.22% | +84.46% | 438B | |
| +0.33% | -1.17% | +27.98% | +26.90% | 333B | |
| -0.02% | -2.85% | +25.27% | +44.88% | 282B | |
| -3.89% | -11.22% | +20.78% | +26.07% | 267B | |
| +0.66% | -1.42% | -29.26% | -39.30% | 218B | |
| -0.06% | -2.88% | +20.98% | +61.70% | 196B | |
| -3.72% | -1.10% | +13.35% | +71.53% | 161B | |
| Average | -0.79% | -2.63% | +26.65% | +65.59% | 359.13B | |
| Weighted average by Cap. | -0.56% | -2.93% | +35.34% | +81.63% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 190B 2B 1.75B 1.61B 1.49B 2.82B 2.87B 19.25B 7.56B 93.83B 7.5B 7.34B 323B | 214B 2.24B 1.96B 1.81B 1.67B 3.17B 3.23B 21.64B 8.5B 105B 8.43B 8.24B 363B |
| Net income | 24.86B 261M 228M 210M 194M 369M 375M 2.51B 987M 12.25B 979M 957M 42.1B | 33.98B 356M 312M 287M 265M 504M 512M 3.43B 1.35B 16.74B 1.34B 1.31B 57.54B |
| Net Debt | 114B 1.2B 1.05B 968M 894M 1.7B 1.72B 11.56B 4.54B 56.35B 4.5B 4.41B 194B | 82.03B 860M 752M 694M 641M 1.22B 1.24B 8.29B 3.26B 40.41B 3.23B 3.16B 139B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-10 | ₹4,903.35 | +0.14% | 40,721 |
| 26-07-09 | ₹4,896.65 | +0.60% | 11,846 |
| 26-07-08 | ₹4,867.45 | +0.27% | 10,378 |
| 26-07-07 | ₹4,854.25 | +0.64% | 8,639 |
| 26-07-06 | ₹4,823.40 | +1.21% | 5,327 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TORNTPHARM Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
